<DOC>
	<DOCNO>NCT00215605</DOCNO>
	<brief_summary>The purpose study determine best safe dose XL184 administer orally . XL184 new chemical entity inhibit VEGFR2 , MET RET , kinases implicated tumor formation , growth migration . To determine high safe dose , subject receive different amount drug . The first group subject receive low dose XL184 . As long medically unacceptable side effect note , dose increased next group . When maximum tolerate dose ( MTD ) reach , least 20 subject Medullary Thyroid Cancer ( MTC ) enrol evaluate effect XL184 population .</brief_summary>
	<brief_title>Study XL184 ( Cabozantinib ) Adults With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Histologically confirm advanced malignancy ( solid tumor lymphoma ) metastatic unresectable standard curative measure exist longer effective Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 Life expectancy great 3 month Adequate organ marrow function Written inform consent Use acceptable method contraception course study 3 month completion study In MTD expand cohort : least 20 subject metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer appropriate surgical resection measurable disease define RECIST Chemotherapy , immunotherapy radiation within 4 week ( nitrosoureas mitomycin C within 6 week ) first schedule dose XL184 Administration investigational drug within 30 day first dose XL184 Subject recover adverse event due investigational agent medication administer 4 week study enrollment Known brain metastasis Uncontrolled intercurrent illness Pregnancy breastfeed Known HIV positive Known allergy hypersensitivity component XL184 formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Advanced Malignancies</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Medullary Thyroid Cancer</keyword>
</DOC>